On the other hand, GCK activators (GKAs) have been reported to cause adverse effects including hyperlipidemia, hepatic fat accumulation and hepatic steatosis, in addition to hypoglycemic effects in both clinical trials [9,10,11] and animal studies [12,13], indicating the potential roles of GCK in maintaining lipid homeostasis. The gene discussed is GCK; the disease is hyperlipidemia.